Abstract
Pharmacovigilance encompasses the detection, assessment, understanding and prevention of drug-related adverse outcomes. This important discipline plays a key role in evaluating drug safety and efficacy under real-world conditions of use following market authorization. Pharmacovigilance focuses mainly on adverse drug reactions (ADRs), which are unintended adverse medical events caused by an approved drug used at normal human doses for the prophylaxis, diagnosis, or therapy of disease, or for modification of physiological function. Spontaneous reporting of ADRs is a key source of pharmacovigilance data on marketed drugs. Analytic pharmacoepidemiologic studies can also be used to study real world safety and effectiveness (RWSE) of marketed drugs. Evaluation of spontaneous reporting data is often referred to as passive pharmacovigilance, with analytic epidemiological studies based on electronic health records or claims data representing active surveillance.
Pharmacovigilance has contributed substantially to our knowledge of the safety of antiparkinsonian drugs. Though patients on dopamine agonists and/or L-DOPA usually develop diurnal somnolence or impulse-control disorders, because they only occur infrequently, they were only identified in the marketing phase by spontaneous reporting of the adverse events. Tolcapone has been shown to produce fulminant hepatitis with a very low frequency, an adverse effect that was unnoticed during premarketing clinical development. Heart valvular disorders in patients treated with ergolinic dopamine agonists were also identified using spontaneous reporting data and later confirmed by large-scale pharmacoepidemiologic studies. Heart failure has been related to pramipexole use by several pharmacoepidemiological studies, after a signal was detected in phase III clinical trials. In this chapter, the main concepts underlying modern pharmacovigilance are outlined, along with the specific role of pharmacovigilance in assessing the safety of antiparkinsonian drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
World Health Organization Collaborating Centre for International Drug Monitoring (2002) Safety of Medicines. A guide to detecting and reporting adverse drug reactions. World Health Organization, Geneva
Bord CA, Rach CL (2006) Adverse drug reactions in United States hospitals. Pharmacotherapy 26:601–608
World Health Organization Collaborating Centre for International Drug Monitoring (2002) The importance of pharmacovigilance. Safety monitoring of medicinal products. World Health Organization, Geneva
The Council of the European Economic Community (1906) Directive 65/65/EEC of the 26 Jan 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products. The Council of the European Economic Community, Brussels
Montastruc JL, Sommet A, Lacroix I et al (2006) Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 73:629–632
Rehan HS, Chopra D, Kakkar AK (2009) Physician’s guide to pharmacovigilance: terminology and causality assessment. Eur J Intern Med 20:3–8
Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72:S1–S136
Strom BL (2000) What is pharmacoepidemiology? In: Strom BL (ed) Pharmacoepidemiology. Wiley & Sons, New York, NY, pp 3–15
Uher R, Farmer A, Henigsberg N et al (2009) Adverse reactions to antidepressants. Br J Psychiatry 195:202–210
Balatsinou L, Di GG, Sabatino G et al (2004) Asthma worsened by benzoate contained in some antiasthmatic drugs. Int J Immunopathol Pharmacol 17:225–226
Brown MB, Traynor MJ, Martin GP et al (2008) Transdermal drug delivery systems: skin perturbation devices. Methods Mol Biol 437:119–139
Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259
Mcbride WG (1961) Thalidomide and congenital malformations. Lancet 2:1358–1358
Vargesson N (2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 105:140–156
Greene JA, Podolsky SH (2012) Reform, regulation, and pharmaceuticals—the Kefauver-Harris amendments at 50. N Engl J Med 367:1481–1483
Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359:248–252
Grimes DA, Schulz KF (2002) An overview of clinical research: the lay of the land. Lancet 359:57–61
Mann RD (2007) An instructive example of a long-latency adverse drug reaction—sclerosing peritonitis due to practolol. Pharmacoepidemiol Drug Saf 16:1211–1216
Harmark L, Van Grootheest AC (2008) Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 64:743–752
World Health Organization Collaborating Centre for International Drug Monitoring (2000) Safety monitoring of medicinal products: guidelines for setting up and running a Pharmacovigilance Centre. World Health Organization, Geneva
World Health Organization Collaborating Centre for International Drug Monitoring (2019) Uppsala Monitoring Centre: VigiBase. World Health Organization, Geneva
Olivier P, Montastruc JL (2006) The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf 15:808–812
Mcnaughton R, Huet G, Shakir S (2014) An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open 4:e004221
Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385–396
Stephenson WP, Hauben M (2007) Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 16:359–365
Weaver J, Willy M, Avigan M (2008) Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J 10:35–41
Chan EW, Liu KQ, Chui CS et al (2015) Adverse drug reactions – examples of detection of rare events using databases. Br J Clin Pharmacol 80:855–861
Robb MA, Racoosin JA, Sherman RE et al (2012) The US Food and Drug Administration’s sentinel initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf 21(Suppl 1):9–11
Ordonez L, Salgueiro E, Jimeno FJ et al (2015) Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs. Eur Rev Med Pharmacol Sci 19:2732–2737
Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245
Kramer MS, Leventhal JM, Hutchinson TA et al (1979) An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 242:623–632
Karch FE, Lasagna L (1975) Adverse drug reactions. A critical review. JAMA 234:1236–1241
Begaud B, Evreux JC, Jouglard J et al (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111–118
Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384–386
Cantor CR, Stern MB (2002) Dopamine agonists and sleep in Parkinson's disease. Neurology 58:S71–S78
Frucht S, Rogers JD, Greene PE et al (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908–1910
Ferreira JJ, Galitzky M, Montastruc JL et al (2000) Sleep attacks and Parkinson’s disease treatment. Lancet 355:1333–1334
Ferreira JJ, Thalamas C, Montastruc JL et al (2001) Levodopa monotherapy can induce “sleep attacks” in Parkinson’s disease patients. J Neurol 248:426–427
Homann CN, Wenzel K, Suppan K et al (2002) Sleep attacks in patients taking dopamine agonists: review. BMJ 324:1483–1487
Micallef J, Rey M, Eusebio A et al (2009) Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 67:333–340
Giovannoni G, O'sullivan JD, Turner K et al (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423–428
Antonini A, Cilia R (2009) Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf 32:475–488
Voon V, Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64:1089–1096
Voon V, Thomsen T, Miyasaki JM et al (2007) Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64:212–216
Perez-Lloret S, Rey MV, Fabre N et al (2012) Do Parkinson’s disease patients disclose their adverse events spontaneously? Eur J Clin Pharmacol 68:857–865
Assal F, Spahr L, Hadengue A et al (1998) Tolcapone and fulminant hepatitis. Lancet 352:958
Colosimo C (1999) The rise and fall of tolcapone. J Neurol 246:880–882
Benabou R, Waters C (2003) Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson’s disease. Expert Opin Drug Saf 2:263–267
Borges N (2005) Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 4:69–73
Pritchett AM, Morrison JF, Edwards WD et al (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280–1286
Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829
Steiger M, Jost W, Grandas F et al (2009) Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review. J Neural Transm 116:179–191
Bhattacharyya S, Schapira AH, Mikhailidis DP et al (2009) Drug-induced fibrotic valvular heart disease. Lancet 374:577–585
Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38
Perez-Lloret S, Rey MV, Crispo J et al (2014) Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin Drug Saf 13:351–360
Administration USFDA (2012) FDA drug safety communication: ongoing safety review of Parkinson’s drug Mirapex (pramipexole) and possible risk of heart failure. FDA, Silver Spring, MD
Arbouw ME, Movig KL, Guchelaar HJ et al (2012) Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case-control study. Eur J Clin Pharmacol 68:83–88
Mokhles MM, Trifiro G, Dieleman JP et al (2012) The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol Res 65:358–364
Renoux C, Dell'aniello S, Brophy JM et al (2012) Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf 21:34–41
Hsieh PH, Hsiao FY (2013) Risk of heart failure associated with dopamine agonists: a nested case-control study. Drugs Aging 30:739–745
Crispo J, Willis AW, Thibault DP et al (2016) Associations between cardiovascular events and nonergot dopamine agonists in Parkinson’s disease. Mov Disord Clin Pract 2016:1–11
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix
Appendix
Adverse event or experience: any untoward medical occurrence that may present during treatment with a medicine but which does not necessarily have a causal relationship with this treatment . The basic point here is the coincidence in time without any suspicion of a causal relationship.
Serious adverse event: any event that: is fatal; is life-threatening; is permanently/significantly disabling; requires or prolongs hospitalization; causes a congenital anomaly; or requires intervention to prevent permanent impairment or damage.
Adverse drug reaction (ADR): a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function. In this description it is of importance that it concerns the response of a patient, in which individual factors may play an important role, and that the phenomenon is noxious (an unexpected therapeutic response, for example, may be a side effect but not an adverse reaction).
Unexpected adverse reaction: an adverse reaction, the nature or severity of which is not consistent with domestic labeling or market authorization, or expected from characteristics of the drug.
Side effect: an unintended pharmacodynamic effect of a pharmaceutical product occurring at doses normally used by a patient which is related to the pharmacological properties of the drug.
Modified from: Safety of Medicines, A guide to detecting and reporting adverse drug reactions . WHO, Geneva, 2002 [1].
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Perez-Lloret, S., Crispo, J.A.G., Rey, M.V., Mattison, D., Krewski, D. (2021). Value and Methods of Pharmacovigilance in the Monitoring of Drug Safety in Parkinson’s Disease. In: Perez-Lloret, S. (eds) Clinical Trials In Parkinson's Disease. Neuromethods, vol 160. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0912-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0912-5_8
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0911-8
Online ISBN: 978-1-0716-0912-5
eBook Packages: Springer Protocols